Investor Relations

Rigel's Mission

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.

Rigel Announces Conference Call and Webcast to Report Second Quarter 2021 Financial Results and Business Update

View Press Release View All

Jul 14, 2021 • 7:30am EDT

New TAVALISSE® Data Analyses To Be Presented at International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress

Jun 29, 2021 • 7:30am EDT

Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial

May 26, 2021 • 7:30am EDT

Rigel to Present at the Jefferies Virtual Healthcare Conference

June 2021

View Presentation

Second Quarter 2021 Financial Results Conference Call

View Event Add to Calendar View All

Q1 2021

Quarter Ended Mar 31, 2021

Earnings Release

PDF HTML

Audio

Earnings Webcast

Earnings Presentation

PDF

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2020

Investor Contact Information

Company

Rigel Pharmaceuticals, Inc.
1180 Veterans Blvd
South San Francisco, CA 94080